URGN · NASDAQ · Biotechnology

UroGen Pharma

Develops localized mitomycin therapies for low-grade urothelial cancers.

$43.62
After-hours close−0.01 (−0.02%)
At close$43.63(−4.11%)
DateEstimateReportedSurprise
Nov 2026$0.10
Aug 2026−$0.27−$0.28−5.7%
May 2026−$0.56−$0.47+16.1%
Mar 2026−$0.52−$0.54−4.2%
Nov 2025−$0.72−$0.69+4.2%

The latest year is open to everyone — the 41 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Aug 2020
May 2020
Mar 2020
Nov 2019
Aug 2019
May 2019
Feb 2019
Nov 2018
Aug 2018
May 2018
Mar 2018
Nov 2017
Aug 2017
May 2017
Mar 2017
Sep 2016
Jun 2016
Mar 2016
Dec 2015
Mar 2015
Dec 2014
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 5, 2026$0.10$90.6M
Aug 5, 2026−$0.27−$0.28−5.7%$63.5M$72.5M+14.0%
May 6, 2026−$0.56−$0.47+16.1%$44.8M$51.0M+13.7%
Mar 2, 2026−$0.52−$0.54−4.2%$39.9M$37.8M−5.2%
Nov 6, 2025−$0.72−$0.69+4.2%$40.1M$27.5M−31.5%

The latest year is open to everyone — the 41 quarters behind it read with an account.

Sign in
Aug 7, 2025
May 12, 2025
Mar 10, 2025
Nov 6, 2024
Aug 13, 2024
May 13, 2024
Mar 14, 2024
Nov 14, 2023
Aug 10, 2023
May 11, 2023
Mar 16, 2023
Nov 10, 2022
Aug 11, 2022
May 10, 2022
Mar 21, 2022
Nov 15, 2021
Aug 4, 2021
May 13, 2021
Mar 18, 2021
Nov 9, 2020
Aug 10, 2020
May 7, 2020
Mar 2, 2020
Nov 12, 2019
Aug 9, 2019
May 9, 2019
Feb 28, 2019
Nov 12, 2018
Aug 14, 2018
May 15, 2018
Mar 15, 2018
Nov 14, 2017
Aug 14, 2017
May 6, 2017
Mar 31, 2017
Sep 30, 2016
Jun 30, 2016
Mar 31, 2016
Dec 31, 2015
Mar 31, 2015
Dec 31, 2014